Using advanced imaging techniques to improve diagnosis and management of gastric cancer
Official title: Diagnostic and Predictive Performance of Dual-/ Muti- Energy CT and MRI in the Treatment Response and Survival Prognosis of Gastric Cancer
Run by The First Affiliated Hospital of Zhengzhou University · NCT06869694 · Data updated 2026-11-12
This study is testing whether advanced imaging techniques can help doctors better diagnose and manage gastric cancer in patients who are about to have surgery.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 300 (estimated) |
| Sponsor | The First Affiliated Hospital of Zhengzhou University Academic / other |
| Locations | 1 site (Zhengzhou, China) |
| Status | Recruiting |
| Started | September 1, 2024 |
| Main results expected | September 1, 2026 |
| Study ends | September 1, 2028 |
| Registry record updated | March 11, 2025 |
| Trial ID | NCT06869694 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are patients with a pathological biopsy-confirmed diagnosis of gastric cancer who are scheduled for radical gastrectomy.
✕Probably not a fit
Patients who refuse to sign informed consent or have poor-quality imaging that cannot provide clear results may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study aims to enhance the preoperative assessment of gastric cancer by evaluating the effectiveness of multi-parametric magnetic resonance imaging (mpMRI) and advanced CT techniques, including Dual-/Multi-energy CT and photon-counting Detector CT (PCD-CT). By accurately predicting risk stratification, treatment response, and survival prognosis, the study seeks to inform clinical treatment decisions and ultimately improve patient outcomes. Participants will include patients with confirmed gastric cancer who are undergoing surgical procedures. The study will analyze imaging results to determine their impact on management strategies.
Why it matters
Potential benefit: If successful, this study could lead to more accurate diagnoses and better treatment planning for patients with gastric cancer.
How similar studies have gone: Other studies utilizing advanced imaging techniques for cancer diagnosis have shown promising results, indicating potential success for this approach.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Pathological biopsy confirmed gastric cancer; 2. Surgery: patients undergoing radical gastrectomy. Patients undergoing exploratory abdominal surgery or palliative tumor resection were still included in the study when peritoneal metastasis or adjacent organ invasion was identified intraoperatively and radical surgical resection was not possible. Exclusion Criteria: 1. Refusal or inability to sign informed consent; 2. CT or MRI images are poor or the focus is small and CT images are not clear; 3. Patients with other tumors complicated with patients with important organ dysfunction.
Where it's running
-
The First Affiliated Hospital of Zhengzhou University
Zhengzhou, China, China Recruiting
Study contacts
- Study coordinator: Zihao Zhao, Dr
- Email: zzh2020@163.com
- Phone: 0371-66271387
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
CG-7321: a first-in-human test in advanced solid tumors
We’re testing CG-7321 alone and with fulvestrant to see if it’s safe and tolerable in adults with advanced solid tumors.
-
Neoadjuvant trastuzumab, durvalumab, and FLOT for HER2-positive gastric or GEJ cancer
This study tests a pre-surgery treatment combining trastuzumab, durvalumab, and FLOT for patients with HER2-positive locally advanced gastric or gastroesophageal junction cancer to see how many achieve complete tumor disappearance.
-
Integrated genomic and clinical database for cancer biomarker discovery
Researchers are building a combined genomic and clinical database at Samsung Medical Center to test biomarkers for cancer diagnosis, treatment choice, and predicting how well treatments work.
-
Adding 2141-V11 to standard therapy for advanced esophageal, gastric, or gastroesophageal junction cancer
This study tests whether adding the drug 2141-V11 to standard anti-PD-1 therapy (with or without 5-FU) is safe for adults with advanced or metastatic esophageal, gastric, or gastroesophageal junction adenocarcinoma.
-
Guaraná Supplement for Cancer-Related Fatigue in People Undergoing Treatment
This study tests whether taking guaraná capsules helps reduce cancer-related fatigue and improve quality of life in adults with breast, lung, colorectal, or gastric cancer who are actively receiving treatment.
-
ABBV-253 in adults with advanced solid tumors
This study tests ABBV-253 to see if it is safe, how it affects the cancer, and how the drug moves in the body for adults with advanced solid tumors.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.